A Novel Insight Into the Mechanism of Pulmonary Hypertension Involving Caveolin-1 Deficiency and Endothelial Nitric Oxide Synthase Activation

Trends in Cardiovascular Medicine

Volumn 19, Issue 7, 2009, Pages 238-242

  Zhao, You Yang ^a   Malik, Asrar B ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; GENE DELETION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; CAVEOLIN 1; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; HUMANS; HYPERTENSION, PULMONARY; MICE; NITRIC OXIDE SYNTHASE TYPE III; TYROSINE;

EID: 77951293073     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2010.02.003     Document Type: Review

References (38)

1. Achcar R.O., Demura Y., Rai P.R., et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006, 129:696-705.
2. Beckman J.S., Beckman T.W., Chen J., et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87:1620-1624.
3. Bowers R., Cool C., Murphy R.C., et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004, 169:764-769.
4. Bucci M., Gratton J.P., Rudic R.D., et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000, 6:1362-1367.
5. Cohen A.W., Hnasko R., Schubert W., Lisanti M.P. Role of caveolae and caveolins in health and disease. Physiol Rev 2004, 84:1341-1379.
6. Cracowski J.L., Cracowski C., Bessard G., et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001, 164:1038-1042.
7. Drab M., Verkade P., Elger M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
8. Farber H.W. The status of pulmonary arterial hypertension in 2008. Circulation 2008, 117:2966-2968.
9. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004, 351:1655-1665.
10. Feron O., Belhassen L., Kobzik L., et al. Endothelial nitric oxide synthase targeting to caveolae: Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996, 271:22810-22814.
11. Feron O., Dessy C., Moniotte S., et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999, 103:897-905.
12. Galbiati F., Razani B., Lisanti M.P. Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411.
13. Hoshikawa Y., Ono S., Suzuki S., et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001, 90:1299-12306.
14. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
15. Hurst J.K. Whence nitrotyrosine?. J Clin Invest 2002, 109:1287-1289.
16. Ignarro L.J., Cirino G., Casini A., Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999, 34:879-886.
17. Jasmin J.F., Mercier I., Dupuis J., et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006, 114:912-920.
18. Ju H., Zou R., Venema V.J., Venema R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 1997, 272:18522-18525.
19. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000, 26:81-84.
20. Machado R.D., Aldred M.A., James V., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27:121-132.
21. Maniatis N.A., Shinin V., Schraufnagel D.E., et al. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice. Am J Physiol Lung Cell Mol Physiol 2008, 294:L865-L873.
22. Mason N.A., Springall D.R., Burke M., et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 1998, 185:313-318.
23. Mathew R., Huang J., Shah M., et al. Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004, 110:1499-1506.
24. Michel J.B., Feron O., Sacks D., Michel T. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997, 272:15583-15586.
25. Negash S., Gao Y., Zhou W., et al. Regulation of cGMP-dependent protein kinase-mediated vasodilation by hypoxia-induced reactive species in ovine fetal pulmonary veins. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1012-L1020.
26. Nozik-Grayck E., Stenmark K.R. Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. Adv Exp Med Biol 2007, 618:101-112.
27. Ozaki M., Kawashima S., Yamashita T., et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 2001, 37:322-327.
28. Patel H.H., Zhang S., Murray F., et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. Faseb J 2007, 21:2970-2979.
29. Puri A., McGoon M.D., Kushwaha S.S. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007, 4:319-329.
30. Rabinovitch M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc Res 1997, 34:268-272.
31. Razani B., Engelman J.A., Wang X.B., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138.
32. Rothberg K.G., Heuser J.E., Donzell W.C., et al. Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68:673-682.
33. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997, 336:111-117.
34. Runo J.R., Loyd J.E. Primary pulmonary hypertension. Lancet 2003, 361:1533-1544.
35. Wunderlich C., Schmeisser A., Heerwagen C., et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther 2008, 21:507-515.
36. Zhao Y.Y., Liu Y., Stan R.V., et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 2002, 99:11375-11380.
37. Zhao Y.D., Courtman D.W., Deng Y., et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005, 96:442-450.
38. Zhao Y.Y., Zhao Y.D., Mirza M.K., et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009, 119:2009-2018.